Company

With the pro­vi­sion of hu­man mi­cro­phys­i­o­log­i­cal sys­tems / or­gan-on-chip tech­nol­o­gy, Dy­nam­ic42 GmbH ad­dresses crit­i­cal points in the de­vel­op­ment of ap­pli­ca­tions for many ar­eas where chem­i­cal sub­stances and bi­o­log­i­cal com­pounds come into di­rect contact with hu­mans or are used in prod­ucts for hu­mans. Here, we con­tribute to in­crease the va­lid­ity of data ob­tained dur­ing pre-clin­i­cal trial phases by test­ing on hu­man mi­cro­phys­i­o­log­i­cal or­gan mod­els. Thus, re­sults are bet­ter trans­fer­able into the hu­man sit­u­a­tion in clin­i­cal trial phas­es.

To achieve this, we of­fer a ma­jor ad­van­tage with many years of ex­per­tise in han­dling and in­te­grat­ing im­mune cells into our hu­man mi­cro­phys­i­o­log­i­cal mod­els as tis­sue-res­i­dent com­po­nents or via the cir­cu­la­tion within the cell cul­ture me­dia.

On the one hand, test­ing in our hu­man mi­cro­phys­i­o­log­i­cal mod­els will im­prove the de­vel­op­ment of com­pounds with less side ef­fects for hu­mans. On the other hand, chances of costly ad­just­ments or even ter­mi­na­tion of stud­ies in late-stage clin­i­cal trial phases will be re­duced.

Con­comi­tant, we strive to re­duce an­i­mal ex­per­i­men­ta­tion by us­ing our mi­cro­phys­i­o­log­i­cal sys­tems. Due to their cel­lu­lar com­plex­i­ty, they of­fer in­creased data va­lid­ity com­pared to stan­dard cell cul­ture of in­di­vid­ual cell types. Sub­se­quent­ly, an­i­mal ex­per­i­men­ta­tion can thus be kept at a min­i­mal lev­el. Fur­ther, if the de­vel­op­ment of a stan­dard al­ter­na­tive test method is con­sid­ered for in­di­vid­ual ap­pli­ca­tions, we would like to con­tribute to es­tab­lish and pro­vide so­lu­tions in those cas­es.

Our com­pany would like to con­tribute to the eco­nom­i­cal and sus­tain­able de­vel­op­ment of phar­ma­ceu­ti­cals and ad­di­tives. We want to dis­trib­ute mod­ern, hu­man cell cul­ture-based so­lu­tions with in­te­grated lat­est tech­nolo­gies in or­der to min­i­mize or re­place an­i­mal ex­per­i­men­ta­tion. Thus, our prin­ci­ple is to pro­mote eth­i­cal val­ues and sus­tain­abil­ity in re­search and de­vel­op­ment.

Sec­ond­ly, the well-be­ing of hu­mans rep­re­sents an im­por­tant value to our com­pa­nies iden­ti­ty. The im­prove­ment of de­vel­op­men­tal pro­ce­dures and test meth­ods by us­ing com­plex hu­man mi­cro­phys­i­o­log­i­cal or­gan mod­els en­ables an in­crease in safety of newly de­vel­oped drugs and ad­di­tives and de­creases their chance in bear­ing se­vere side ef­fects. Our daily mo­ti­va­tion is to de­velop new ap­pli­ca­tions as well as to im­prove and tech­no­log­i­cally ex­pand our plat­form to achieve these goals.